CELL AND GENE THERAPY INSIGHTS

Filter by Interests

Filter by ContentType

How to expedite clinical development of oncology agents: overcoming complexities of early-phase oncology trials for ATMPs

How to expedite clinical development of oncology agents: overcoming complexities of early-phase oncology trials for ATMPs

Harriet Gray Stephens
29 September 2023
Viewpoint
 iNKT cells for allogeneic cell therapy

iNKT cells for allogeneic cell therapy

Eleni Chantzoura, Paul Ibbett
31 August 2023
Viewpoint
 Harnessing the untapped potential of commensal viruses in genetic medicine

Harnessing the untapped potential of commensal viruses in genetic medicine

Joseph Cabral
04 May 2023
Viewpoint
 Advancing best-in-class allogeneic CAR-T therapies

Advancing best-in-class allogeneic CAR-T therapies

Blair Madison
16 April 2023
Viewpoint
 Preclinical safety assessment in therapeutic genome editing

Preclinical safety assessment in therapeutic genome editing

Roberto Nitsch
10 March 2023
Viewpoint
 Addressing gene therapy translational R&D bottlenecks in the CNS

Addressing gene therapy translational R&D bottlenecks in the CNS

Anindya Sen
09 March 2023
Viewpoint
 Current trends in advanced therapy development & commercialization for rare diseases

Current trends in advanced therapy development & commercialization for rare diseases

Alan Boyd
28 February 2023
Viewpoint
 Key considerations when translating a cell therapy product into the clinic

Key considerations when translating a cell therapy product into the clinic

Anthony Ting
06 February 2023
Viewpoint
 Lessons in scientific endeavor and innovation

Lessons in scientific endeavor and innovation

Irving Weissman
04 September 2022
Viewpoint
 In vivo engineering of CAR T cell therapies

In vivo engineering of CAR T cell therapies

Haig Aghajanian
30 August 2022
Viewpoint
 A journey in synthetic biology: using gene circuit technology in immuno-oncology

A journey in synthetic biology: using gene circuit technology in immuno-oncology

Timothy Lu, James Collins
25 August 2022
Viewpoint
 The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies

The power of combining iPSC-derived NK cell therapy & NK-cell engager antibodies

Dr Wei Li, Dr Daniel Teper
22 July 2022
Viewpoint
 Recent gene-editing guidance from FDA – clarifies some gene-editing development questions with room for additional recommendations

Recent gene-editing guidance from FDA – clarifies some gene-editing development questions with room for additional recommendations

Kathleen Candando, Karl Whitney
10 July 2022
Viewpoint
 Will the COVID-19 pandemic lead to a rebirth of research and education on vaccinations in pregnancy?

Will the COVID-19 pandemic lead to a rebirth of research and education on vaccinations in pregnancy?

Emily Adhikari, Jessica Pruszynski, Catherine Spong
10 May 2022
Viewpoint
 Overcoming the immune-related shortfalls of AAV

Overcoming the immune-related shortfalls of AAV

Genine Winslow
10 May 2022
Viewpoint
 Developing broadly protective strategies to protect against future pandemic threats

Developing broadly protective strategies to protect against future pandemic threats

Ralph Baric
06 May 2022
Viewpoint
 The end of an era of cancer drug discovery: life without new drug targets

The end of an era of cancer drug discovery: life without new drug targets

Armen Mardiros, Alexander Kamb
12 April 2022
Viewpoint
 A bright future for lipid nanoparticles in gene therapy

A bright future for lipid nanoparticles in gene therapy

Hongwei Zhang
09 July 2021
Viewpoint
 Leveraging the advantages of liquid biopsy for predictive and prognostic biomarkers in R&D

Leveraging the advantages of liquid biopsy for predictive and prognostic biomarkers in R&D

Chamindie Punyadeera
14 June 2021
Viewpoint
 Allogeneic T-cell therapies: from R&D lab to production facility

Allogeneic T-cell therapies: from R&D lab to production facility

Jakob Dupont, M.D., Joe Newell
09 June 2021
Viewpoint